Codeine is a notable CYP2D6 substrate, and individuals who are poor metabolizers will experience minimal analgesia while ultrarapid metabolizers will be at significant risk for respiratory depression and mortality [86]. This evidence concerns the gene CYP2D6 and Respiratory insufficiency due to muscle weakness.